Efficacy and Safety of CKD-828 to Stage 2 Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.
Also called NCT01634295
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 103 participants
- Registry
-
NCT01634295
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01634295. Randomized; triple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of CKD-828 to Stage 2 Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- CKD-828 2.5/40mg
- Intervention (Drug)
- CKD-828 5/40mg
- Intervention (Drug)
- CKD-828 5/80mg
- Intervention (Drug)
- S-amlodipine 2.5mg
- Intervention (Drug)
- S-amlodipine 5mg
- Lead sponsor
- Chong Kun Dang Pharmaceutical
Record details
- Record id
cardio:ct-nct01634295- Content hash
4b0ea45628ab7ee12d761c2aa1f92636f24804fcc5cc30e096d6478b0031db93